1. Home
  2. AIRS vs RZLT Comparison

AIRS vs RZLT Comparison

Compare AIRS & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AIRS

AirSculpt Technologies Inc.

HOLD

Current Price

$2.18

Market Cap

166.3M

Sector

Health Care

ML Signal

HOLD

Logo Rezolute Inc. (NV)

RZLT

Rezolute Inc. (NV)

HOLD

Current Price

$1.91

Market Cap

187.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIRS
RZLT
Founded
2012
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
166.3M
187.3M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
AIRS
RZLT
Price
$2.18
$1.91
Analyst Decision
Hold
Strong Buy
Analyst Count
2
6
Target Price
$3.75
$12.33
AVG Volume (30 Days)
603.5K
15.4M
Earning Date
11-07-2025
02-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$157,554,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.55
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.53
$1.07
52 Week High
$12.00
$11.46

Technical Indicators

Market Signals
Indicator
AIRS
RZLT
Relative Strength Index (RSI) 32.44 29.33
Support Level $1.83 $2.16
Resistance Level $2.24 $2.43
Average True Range (ATR) 0.18 0.31
MACD 0.15 0.12
Stochastic Oscillator 43.87 24.27

Price Performance

Historical Comparison
AIRS
RZLT

About AIRS AirSculpt Technologies Inc.

AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.

Share on Social Networks: